Key result
Advanced diagnostics help characterize acute antibody-mediated rejection but targeted immunosuppression efficacy remains unproven.
Advances in diagnostic techniques like C4d deposition and flow cytometry for anti-HLA antibodies assist in characterizing acute antibody-mediated rejection in heart transplantation, though optimal immunosuppressive strategies remain to be proven.
Answers are grounded in this paper and cite their sources.
May aid acute AMR characterization in heart transplant; leaves B-lymphocyte targeted and mTOR inhibitor efficacy unproven.
Acute antibody-mediated rejection (AMR) in heart transplantation is often associated with hemodynamic compromise, and is associated with increased mortality and development of accelerated transplant coronary artery disease (TCAD). The diagnosis of AMR has historically been controversial and outcomes with aggressive immunosuppressive therapy including plasmapheresis and cyclophosphamide are poor. Advances in diagnostic techniques like the demonstration of immunopathologic evidence for antibody-mediated rejection by deposition of the complement split product C4d in tissue and detection of anti-HLA antibodies by flow cytometry will assist in further characterizing AMR. Immunosuppression targeting B-lymphocytes and use of m-TOR inhibitors to alter the predilection to develop TCAD and improve survival in AMR remains to be proven.
No takes yet. Share an insight, caveat, or question.
Uber et al. (2007) conducted a review in Acute antibody-mediated rejection in heart transplantation. Advances in diagnostic techniques assist in characterizing acute antibody-mediated rejection, though the efficacy of B-lymphocyte targeted immunosuppression and m-TOR inhibitors remains to be proven.
Synapse has enriched 10 related papers. Consider them for comparative context: